nav1.8

Nav1.8-IN-1 (CHEMBL1270208) is an inhibitor of human NaV1.8

Nav1.8-IN-2 (compound 35A) is a potent Nav1.8 inhibitor (IC50: 0.4 nM) and can be utilized in research on pain disorders, cough, and both acute and chronic pruritus.

Nav1.8-IN-4 is a potent Nav1.8 channel inhibitor with potential analgesic activity.Nav1.8-IN-4 can be used for pain and neurological related disorders.

Nav1.8-IN-10 (Compound 6), functioning as a Nav1.8 channel inhibitor, exhibits a 79.4% blocking rate of the Nav1.8 channel at a concentration of 4 nM. This compound is utilized in researching pain disorders [1].

Nav1.8-IN-11 (Example 1), a Nav1.8 channel inhibitor with an IC50 of 0.1 nM, is utilized in research on pain disorders [1].

Nav1.8-IN-12 (Compound 23 R) serves as an inhibitor of the Nav1.8 channel and is utilized in the research of pain-related diseases [1].

Nav1.8-IN-13 (compound 16), functioning as a Nav1.8 inhibitor with a pIC50 value of 7.9, is referenced as [1].

Nav1.8-IN-5 (Example 1), a voltage-gated sodium channel Nav1.8 inhibitor, is applicable in the research of Nav1.8-mediated diseases including pain, pain-related disorders, and cardiovascular diseases (such as atrial fibrillation) [1].

Nav1.8-IN-7 (Example 116) serves as a selective inhibitor of Nav1.8, demonstrating more than 50% inhibition at 100 nM specifically for Nav1.8. It exhibits an IC50 of 15.6 μM for the hERG channel. This compound holds promise in the field of pain research [1].

Nav1.8-IN-8 (Compound A11), a Nav1.8 channel inhibitor, potentially mitigates diseases mediated by sodium ion channels (NaV) [1].

Nav1.8-IN-9 (Example 16), a potent Nav1.8 inhibitor with an IC 50 of 0.084 nM, is orally active and holds promise for extensive pain research [1].

Nav1.8-IN-14 (compound 20) is an effective selective inhibitor of Nav1.8. It is utilized in the research of pain-associated diseases.

Suzetrigine(VX-548) is an orally active and specific NaV1.8 inhibitor. Suzetrigine has analgesic activity and can be used to study acute pain and neurotransmission.

PF-06305591 is an effective and selective blocker of voltage-gated sodium channel NaV1.8 (IC50 = 15 nM).

PF 04531083 is a selective blocker of the NaV1.8 channel. PF 04531083 can be used for neuropathic and inflammatory pain studies.

GX-585 is a sulfonamide analog that is a Nav 1.7 channel inhibitor with analgesic activity for the study of neuropathic pain and inflammation.

Cyfluthrin binds to voltage-sensitive sodium channel such as Nav 1.8 sodium channel and modify their gating kinetics, thereby disrupting nerve function of pests.

A-887826 is a selective, orally bioavailable, and voltage-dependent Na(v1.8) channel blocker (IC50: 11 nM). It attenuates neuropathic tactile allodynia in vivo.

A-803467 is a selective NaV1.8 channel blocker.

PF-04885614 is a potent inhibitor of NaV1.8, has potential for neurological and neurodevelopmental diseases treatment.

TC-N 1752 is an orally active inhibitor of Nav1.7 channel with IC50 of 0.17 μM. TC-N 1752 shows analgesic activities.

PF-01247324 is a selective and orally bioavailable Nav1.8 channel blocker [IC50: 196 nM].

DSP-2230 is a selective blocker of Nav1.7 Nav1.8.

(R)-DSP-2230 is the R-isomer of DSP-2230. DSP-2230 is a selective blocker of Nav1.7 Nav1.8.